Xencor Inc
XNCR14.055USD
+0.115+0.82%
交易中 （美東）報價延遲15分鐘
1.00B總市值
虧損本益比TTM
關於 Xencor Inc 公司
Xencor, Inc. 是一家臨牀階段的生物製藥公司，致力於開發用於治療癌症和其他嚴重疾病的工程抗體。採用其 XmAb 技術設計的 20 多種候選藥物正在臨牀開發中，三種 XmAb 藥物由合作伙伴銷售。其 XmAb 工程技術可以對蛋白質結構進行微小改變，從而產生新的治療作用機制。其全資開發的候選藥物包括 Vudalimab、XmAb819、XmAb808 和 XmAb541。與合作伙伴共同開發的候選藥物包括 Plamotamab。合作伙伴推進的候選藥物包括 Xaluritamig (AMG 509)、ASP2138、JNJ-9401、JNJ-1493 和 Novartis XmAb 未公開的抗體候選藥物。其處於臨牀開發中的細胞因子藥物候選藥物包括 fbalropendekin alfa (XmAb306/RG6323)、XmAb564 和 XmAb662。該公司其他臨牀階段候選藥物包括 Obexelimab、AIMab7195 (XmAb7195) 和 Xpro1595。Vudalimab 是一種針對 PD-1 和 CTLA-4 的雙特異性抗體。
Xencor Inc簡介
公司代碼XNCR
公司名稱Xencor Inc
上市日期Dec 03, 2013
CEODr. Bassil I. Dahiyat, Ph.D.
員工數量250
證券類型Ordinary Share
年結日Dec 03
公司地址465 N. Halstead St.
城市PASADENA
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編91107
電話16263055900
網址https://xencor.com/
公司代碼XNCR
上市日期Dec 03, 2013
CEODr. Bassil I. Dahiyat, Ph.D.
Xencor Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
212.96K
+10.45%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+47.02%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-10.16%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+305.17%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
--
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+427.04%
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
212.96K
+10.45%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+47.02%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-10.16%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+305.17%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
--
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+427.04%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Milestone
25.00M
57.33%
Royalties
18.61M
42.67%
Licensing
0.00
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Milestone
25.00M
57.33%
Royalties
18.61M
42.67%
Licensing
0.00
0.00%
股東統計
更新時間: 8月23日 週六
更新時間: 8月23日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
14.97%
PRIMECAP Management Company
14.76%
The Vanguard Group, Inc.
9.96%
EcoR1 Capital, LLC
8.62%
BVF Partners L.P.
6.48%
其他
45.22%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
14.97%
PRIMECAP Management Company
14.76%
The Vanguard Group, Inc.
9.96%
EcoR1 Capital, LLC
8.62%
BVF Partners L.P.
6.48%
其他
45.22%
股東類型
持股股東
佔比
Investment Advisor
58.35%
Investment Advisor/Hedge Fund
30.36%
Hedge Fund
18.36%
Research Firm
3.89%
Venture Capital
2.85%
Individual Investor
1.31%
Pension Fund
1.01%
Bank and Trust
0.39%
Sovereign Wealth Fund
0.08%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
433
80.42M
112.77%
-5.57M
2025Q2
437
81.68M
114.52%
-1.81M
2025Q1
459
80.70M
113.40%
-3.00M
2024Q4
454
76.54M
108.64%
-2.55M
2024Q3
455
73.66M
105.55%
+3.66M
2024Q2
436
65.64M
106.20%
-4.06M
2024Q1
431
66.91M
108.52%
-498.74K
2023Q4
420
65.39M
107.20%
-1.62M
2023Q3
417
65.14M
107.37%
-1.33M
2023Q2
422
64.91M
107.12%
-2.55M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
10.67M
14.97%
-68.43K
-0.64%
Jun 30, 2025
PRIMECAP Management Company
10.53M
14.76%
+766.31K
+7.85%
Jun 30, 2025
The Vanguard Group, Inc.
8.61M
12.07%
+725.91K
+9.21%
Jun 30, 2025
EcoR1 Capital, LLC
6.14M
8.62%
--
--
Jun 30, 2025
BVF Partners L.P.
2.74M
3.84%
--
--
Jun 30, 2025
State Street Investment Management (US)
3.82M
5.35%
+133.90K
+3.63%
Jun 30, 2025
T. Rowe Price Associates, Inc.
3.65M
5.12%
-176.24K
-4.60%
Jun 30, 2025
TCG Crossover Management, LLC
2.45M
3.44%
--
--
Jun 30, 2025
RTW Investments L.P.
2.40M
3.37%
--
--
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.78M
2.5%
+43.18K
+2.49%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
1.77%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
Invesco NASDAQ Future Gen 200 ETF
0.7%
Invesco S&P SmallCap Health Care ETF
0.53%
ALPS Medical Breakthroughs ETF
0.49%
Inspire Small/Mid Cap ESG ETF
0.28%
SPDR S&P Biotech ETF
0.21%
Direxion Daily S&P Biotech Bull 3X Shares
0.12%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.11%
Invesco Nasdaq Biotechnology ETF
0.09%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比1.77%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.9%
Invesco NASDAQ Future Gen 200 ETF
佔比0.7%
Invesco S&P SmallCap Health Care ETF
佔比0.53%
ALPS Medical Breakthroughs ETF
佔比0.49%
Inspire Small/Mid Cap ESG ETF
佔比0.28%
SPDR S&P Biotech ETF
佔比0.21%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.12%
SPDR SSGA US Small Cap Low Volatility Index ETF
佔比0.11%
Invesco Nasdaq Biotechnology ETF
佔比0.09%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
